ARTICLE | Clinical News
Antisense inhibitors regulatory update
March 20, 2000 8:00 AM UTC
HYBN received U.S. Patent No. 5,968,909 and European Patent No. EP0850300 B1 covering therapeutic antisense compounds with reduced immunostimulatory side effects. ...